Get the Stockscreener App
170.72
0.35%
0.59
After Hours:
170.72
Charles River Laboratories International Inc stock is traded at $170.72, with a volume of 531.28K.
It is up +0.35% in the last 24 hours and up +12.14% over the past month.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
See More
Previous Close:
$170.13
Open:
$170.22
24h Volume:
531.28K
Relative Volume:
0.58
Market Cap:
$8.40B
Revenue:
$4.06B
Net Income/Loss:
$413.08M
P/E Ratio:
21.31
EPS:
8.01
Net Cash Flow:
$560.48M
1W Performance:
-1.59%
1M Performance:
+12.14%
6M Performance:
+61.18%
1Y Performance:
-11.94%
1-Day Range:
$168.71
$173.02
1-Week Range:
$166.86
$174.73
52-Week Range:
$91.86
$230.02
Charles River Laboratories International Inc Stock (CRL) Company Profile
Name
Charles River Laboratories International Inc
Sector
Industry
Phone
781-222-6000
Address
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
170.72 | 8.37B | 4.06B | 413.08M | 560.48M | 8.01 |
|
TMO
Thermo Fisher Scientific Inc
|
527.87 | 198.56B | 43.21B | 6.58B | 6.17B | 17.28 |
|
DHR
Danaher Corp
|
206.10 | 147.61B | 24.01B | 3.41B | 4.86B | 4.7082 |
|
IDXX
Idexx Laboratories Inc
|
639.15 | 50.96B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
139.65 | 39.13B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
203.12 | 34.81B | 15.70B | 1.24B | 2.01B | 6.9036 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-06-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-02-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-09-25 | Upgrade | Jefferies | Hold → Buy |
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| May-23-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| May-14-25 | Upgrade | TD Cowen | Hold → Buy |
| May-08-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-21-25 | Downgrade | Goldman | Buy → Neutral |
| Mar-04-25 | Upgrade | Citigroup | Sell → Neutral |
| Mar-03-25 | Upgrade | Redburn Atlantic | Sell → Neutral |
| Jan-22-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-17-25 | Downgrade | UBS | Buy → Neutral |
| Nov-18-24 | Downgrade | CLSA | Hold → Underperform |
| Nov-07-24 | Upgrade | CLSA | Underperform → Hold |
| Oct-23-24 | Initiated | CLSA | Underperform |
| Oct-14-24 | Initiated | Redburn Atlantic | Sell |
| Oct-07-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-01-24 | Downgrade | Citigroup | Neutral → Sell |
| Aug-08-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-08-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-28-24 | Downgrade | Argus | Buy → Hold |
| Jun-07-24 | Initiated | Mizuho | Neutral |
| Jun-06-24 | Initiated | Goldman | Buy |
| Feb-15-24 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-13-23 | Initiated | TD Cowen | Market Perform |
| Jul-10-23 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-12-23 | Downgrade | Jefferies | Buy → Hold |
| Sep-30-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Aug-04-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-24-22 | Initiated | Guggenheim | Neutral |
| Apr-25-22 | Downgrade | Jefferies | Buy → Hold |
| Apr-07-22 | Initiated | Stephens | Overweight |
| Feb-17-22 | Reiterated | BofA Securities | Buy |
| Feb-17-22 | Upgrade | Citigroup | Neutral → Buy |
| Feb-17-22 | Reiterated | Deutsche Bank | Buy |
| Feb-17-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-17-22 | Reiterated | UBS | Buy |
| Aug-05-21 | Resumed | Credit Suisse | Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-10-20 | Upgrade | Jefferies | Hold → Buy |
| Jul-01-20 | Upgrade | BofA Securities | Neutral → Buy |
| May-13-20 | Upgrade | UBS | Neutral → Buy |
| Apr-21-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-27-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Buy |
| Feb-18-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-10-20 | Upgrade | Goldman | Neutral → Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-18-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-10-19 | Initiated | SVB Leerink | Outperform |
| Apr-30-19 | Resumed | Evercore ISI | Outperform |
| Dec-14-18 | Initiated | Deutsche Bank | Buy |
| Oct-09-18 | Initiated | UBS | Neutral |
| Aug-23-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-17-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-15-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
| Feb-14-18 | Upgrade | SunTrust | Hold → Buy |
View All
Charles River Laboratories International Inc Stock (CRL) Latest News
Charles River Labs forms Scientific Advisory Board to advance NAMs By Investing.com - Investing.com Nigeria
Charles River Labs taps former FDA leader to help move away from animal tests - The Business Journals
Key resistance and support levels for Charles River Laboratories International Inc.July 2025 Recap & Reliable Entry Point Trade Alerts - newser.com
Charles River Announces Scientific Advisory Board to Drive Alternative Method Innovation and Adoptio - PharmiWeb.com
Fairjourney Biologics acquires Charles River Laboratories South San Francisco facility - MSN
Charles River Labs forms Scientific Advisory Board to advance NAMs - Investing.com India
Charles River Announces Scientific Advisory Board to Drive Alternative Method Innovation and Adoption - Business Wire
Can you recover from losses in Charles River Laboratories International Inc.July 2025 Closing Moves & Fast Gain Stock Trading Tips - newser.com
Why Charles River Laboratories International Inc. stock is seen as undervalued2025 Technical Overview & Fast Momentum Stock Entry Tips - newser.com
What does recent volatility data suggest for Charles River Laboratories International Inc.Weekly Investment Recap & Verified Stock Trade Ideas - newser.com
Charles River Laboratories Schedules Third-Quarter 2025 Earnings Release and Conference Call - BioSpace
A Look at Charles River Laboratories' Valuation Following Strategic ReproTracker Partnership with Toxys - simplywall.st
How to integrate Charles River Laboratories International Inc. into portfolio analysis toolsJuly 2025 Final Week & Growth-Oriented Investment Plans - newser.com
Why hedge funds are buying Charles River Laboratories International Inc. stockJuly 2025 Analyst Calls & Long-Term Growth Stock Strategies - newser.com
Will Charles River Laboratories International Inc. (RV6) stock sustain uptrend momentumJuly 2025 Review & Technical Pattern Recognition Alerts - newser.com
Will Charles River Laboratories International Inc. bounce back from current supportQuarterly Profit Review & Target Return Focused Stock Picks - newser.com
Tick level data insight on Charles River Laboratories International Inc. volatilityEntry Point & Real-Time Buy Signal Alerts - newser.com
Understanding Charles River Laboratories International Inc.’s price movement2025 Technical Patterns & Risk Managed Investment Signals - newser.com
TD Cowen Adjusts Price Target on Charles River Laboratories International to $205 From $179, Maintains Buy Rating - MarketScreener
Charles River Laboratories (CRL): Investor Outlook Reveals Potential 8.68% Upside - DirectorsTalk Interviews
Allspring Global Investments Holdings LLC Acquires 516,521 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Laboratories International, Inc. $CRL Shares Sold by Truist Financial Corp - MarketBeat
Could Charles River (CRL) Redefine Its Competitive Edge with New Non-Animal Toxicology Platform? - simplywall.st
Charles River Laboratories International, Inc. $CRL Shares Sold by Lawson Kroeker Investment Management Inc. NE - MarketBeat
Janney Montgomery Scott LLC Has $1.58 Million Stock Position in Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Labs (CRL): Examining Valuation Following Recent Share Price Rebound - Yahoo Finance
Charles River Laboratories International Inc. Stock Underperforms Friday When Compared To Competitors - 富途牛牛
Why Charles River Laboratories International Inc. (RV6) stock is trending on social mediaGlobal Markets & Community Trade Idea Sharing Platform - newser.com
Published on: 2025-10-10 13:12:55 - newser.com
Can Charles River Laboratories International Inc. stock deliver strong Q4 earningsWeekly Risk Report & AI Powered Buy and Sell Recommendations - newser.com
Weiss Ratings Reiterates "Sell (D)" Rating for Charles River Laboratories International (NYSE:CRL) - MarketBeat
Charles River Laboratories International Inc. stock prediction for this weekCPI Data & Expert Approved Momentum Ideas - newser.com
Published on: 2025-10-09 06:30:08 - newser.com
Does Charles River Laboratories International Inc. (RV6) stock trade below intrinsic valueQuarterly Earnings Summary & Real-Time Volume Analysis - newser.com
Is Charles River Laboratories International Inc. (RV6) stock positioned for digital growth eraInsider Buying & Stock Portfolio Risk Control - newser.com
Charles River and Toxys Announce Collaboration to Validate the Use of NAMs for Developmental Toxicity Testing - BioSpace
Winners And Losers Of Q2: Charles River Laboratories (NYSE:CRL) Vs The Rest Of The Drug Development Inputs & Services Stocks - Yahoo Finance
What drives Charles River Laboratories International Inc stock priceMorning Star Patterns & High Yield Portfolio Picks - earlytimes.in
Charles River and Toxys Announce Collaboration to Validate the Use of NAMs for Developmental Toxicit - PharmiWeb.com
Charles River, Toxys Form Partnership on Use of Drug Toxicity Detection Tool - MarketScreener
Charles River (CRL) Partners with Toxys to Enhance Toxicity Testing - GuruFocus
Charles River Laboratories International Inc Stock (CRL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.22%
1.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):